Match tier
Institution-verified
Presence
Current · Arkansas
Last published
2026
Sources
Institutional record
Refreshed
2026-10-05
M
Michael Birrer
Sourced from institutional research profiles (UAMS TRI or ARA).
High Impact
Director
Also affiliated: University of North Carolina at Chapel Hill (2020); University of Copenhagen (2026); Oslo University Hospital (2020–2023); Brigham and Women's Hospital (2006–2007); National Institutes of Health (2000–2008); Harvard University (2017); Washington University in St. Louis (2018); University of Alabama at Birmingham (2019); Massachusetts General Hospital (2017–2023); National Cancer Institute (2000–2008); National Institute of Biomedical Genomics (2020–2023); UNC Lineberger Comprehensive Cancer Center (2020); University of Pennsylvania (2004)
27 h-index
62 pubs
20,276 cited
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Michael Birrer's research focuses on the integrated genomic analyses of human cancers, with a particular emphasis on ovarian carcinoma. He leads a research group at the University of Arkansas for Medical Sciences, where he also serves as Director. His work involves comprehensive characterization of cancer driver genes and mutations, investigating oncogenic signaling pathways, and analyzing the repertoire of mutational signatures across various cancer types.
Birrer has been involved in large-scale collaborative projects, including The Cancer Genome Atlas (TCGA), contributing to pan-cancer analyses of whole genomes and the development of integrated clinical data resources for survival outcome analytics. His publications also explore the immune landscape of cancer and cell-of-origin patterns that define molecular classifications of tumors. His research network includes collaborators such as Zijing Zhang, Lu Huang, Lin-Xi Li, and J. Tucker Andrews, all affiliated with the University of Arkansas for Medical Sciences, with whom he has co-authored multiple publications.
With an h-index of 27 and over 20,000 citations across 62 publications, Birrer is recognized as a highly cited researcher. His recent activity indicates ongoing contributions to the field, with his most recent publication in 2026.
Metrics
- h-index: 27
- Publications: 62
- Citations: 20,276
Positions
-
Director 2019–presentUniversity of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer Institute Institutional directory
Selected Publications
-
Activity of NP-G2-044 (fascin inhibitor) + anti–PD-1 in ICI-resistant advanced/metastatic solid tumors with expansion in cutaneous squamous cell carcinoma (CSCC). (2026)
-
Abstract 3970: Genome wide testing of archived ovarian and uterine carcinosarcoma FFPE tissue using FusionPlus Hi-C to determine HRD status (2026)
-
Quality-of-life outcomes in newly diagnosed advanced cancer: subgroup analysis – a case for individual differences (2026)
-
Abstract A044: Application of HRDefine: a biomarker for identifying root causes of homologous recombination deficiency to a phase 3, randomized, placebo-controlled trial of veliparib in front-line treatment of advanced ovarian cancer (VELIA/GOG-3005) (2025)
-
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer (2025)
-
Single-cell analysis of ovarian myeloid cells identifies age-associated changes in macrophages and signaling dynamics (2025)
-
miRNA(s) expression as predictive biomarkers in recurrent/metastatic cervical cancer: The NRG Oncology/GOG-0240 NIH Cancer Moonshot. (2025)
-
Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha–expressing recurrent ovarian cancer: An integrated safety summary (2024)
-
A spatial proteomic study of platinum-refractory, high-grade serous ovarian cancer implicates dual AKT and WNT activity linked to an immunosuppressive tumor microenvironment (2024)
-
Treatment monitoring utilizing ctDNA-based molecular residual disease detection in early-stage endometrial cancer (2024)
-
A phase 2 study to evaluate efficacy and safety of PRGN-2009, a novel gorilla adenovirus-based immunotherapy, in combination with pembrolizumab versus pembrolizumab monotherapy in patients with recurrent or metastatic cervical cancer. (2024)
-
Single-cell analysis of ovarian myeloid cells identifies aging associated changes in macrophages and signaling dynamics (2024)
-
A phase 2 clinical trial of first-in-class fascin inhibitor NP-G2-044 as monotherapy and in combination therapy with anti-PD-1 immunotherapy in patients with advanced solid tumor malignancies. (2024)
-
Final results of BrUOG 354: A randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas. (2024)
-
BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and fulvestrant (FUL) in HR+/HER2− breast cancer (BC). (2024)
Grants & Funding
As listed on this researcher's institutional profile.
- 3D Spatial Multi-Omics Profiling of Ovarian Cancer NIH/Nat. Cancer Institute via University of Texas M.D. Anderson Cancer Center
- Novel Biomarkers in Ovarian Cancer NIH
- Proteogenomic studies aimed at understanding ovarian tumor responses to agents targeting the DNA damage response and translating this knowledge into clinical benefit NIH
- Treatment of Recurrent, Platinum-Resistant Ovarian Cancer with Glutaminase 1 and PARP Inhibitors US Department of Defense
- A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors Blueprint Medicines Corporation
- The Molecular Genetics of Gynecologic Cancers NIH
- The Genomic, Epigenomic, and Quality-of-Life Characteristics of Long-Term Survivors of Ovarian Cancer Department of Defense
- Regional Cancer Care Facilities and Equipment Health Resources & Services Administration
- Community Project Funding/Congressionally Directed Spending - Construction Health Resources & Services Administration
- A Phase II, Multicenter, Open Label Study of Bintrafusp alfa (M7824) Monotherapy in Participants with Advanced, Unresectable Cervical Cancer with Disease Progression During or After Platinum-Containing Chemotherapy EMD Serono Research & Development Institute via IQVIA, Inc.
- A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients with Unresectable Locally Advanced or Metastatic Cancer Takeda
- NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies Novita Pharmaceuticals, Inc. via Medpace Clinical Research
- Proteomic, Genomic, + Longitudinal Pathways to Ovarian Cancer Biomarker Discovery NIH/Nat. Cancer Institute via Massachusetts General Hospital
- NRG Oncology Network Group Operation Center NIH/Nat. Cancer Institute via NRG Oncology Foundation
- Adult NF Clinic Program Building Pilot Project Children's Tumor Foundation
- Comprehensive Cancer Center Support Grant NIH
- In vivo, noninvasive, ultrasensitive photoacoustic detection of early breast cancer metastasis in bone US Department of the Army
- Validation of a genomic signature that predicts for sub-optimal debulking of epithelial ovarian cancer NIH/Nat. Cancer Institute
- A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy... Artios Pharma Limited
- 3/3 Morehouse School of Medicine/Tuskegee University/University of Alabama at Birmingham O'Neal Comprehensive Cancer Center Partnership NIH
- The FGF18/FGFR4 amplicon: Novel therapeutic biomarkers for ovarian cancer NIH
- Overcoming PARP Inhibitor Resistance of BRCA-Deficient Ovarian Cancers US Department of Defense
- 3D Spatial Multi-Omics Profiling of Ovarian Cancer NIH
- Validation of a genomic signature that predicts for sub-optimal debulking of epithelial ovarian cancer NIH
- Cancer Care Mobile Vans, Computerized Tomography Equipment, and Lung Cancer Screening Health Resources & Services Administration
- The Genomic, Epigenomic, and Quality-of-Life Characteristics of Long-Term Survivors of Ovarian Cancer US Department of Defense
- A Phase 1b Dose Optimization Study of Sovilnesib (an Oral KIF18A Inhibitor) in Subjects with Advanced High Grade Serous Ovarian Cancer Volastra Therapeutics Inc
- Genomic Stratification of Ovarian Cancer Patients NIH
- An Open-Label Study of E7386 in Combination With Other Anticancer Drug(s) in Subjects With Solid Tumors Eisai
- OVARIAN CANCER DETECTION BY UTERINE LAVAGE DNA AND SERUM PROTEINS: A PHASE 2 BIOMARKER STUDY NIH/Nat. Cancer Institute via Massachusetts General Hospital
- The Use of Transcriptional Factors as Targets and Agents in Carcinogenesis NIH
- Cancer Care Mobile Van and Mammography Equipment Health Resources & Services Administration
- 297463 open-label, multicenter, randomized Phase 2 study of ATR inhibitor tuvusertib + PARP inhibitor niraparib or ATM inhibitor lartesertib in participants with BRCA mutant and/or HRD-positive epithelial ovarian cancer progressing on prior PARP therapy. EMD Serono Research & Development Institute via IQVIA, Inc.
Collaboration Network
Top Collaborators
Rebecca C. Arend
University of Alabama at Birmingham (US)
5 shared publications
- Understanding the effect of mechanical forces on ovarian cancer progression
- Utilization of a 3-D tissue engineered model to investigate the effects of perfusion on gynecologic cancer biology
- A spatial proteomic study of platinum refractory HGSOC implicates dual AKT and WNT activity linked to an immunosuppressive tumor microenvironment
- Treatment monitoring utilizing ctDNA-based molecular residual disease detection in early-stage endometrial cancer
- A spatial proteomic study of platinum-refractory, high-grade serous ovarian cancer implicates dual AKT and WNT activity linked to an immunosuppressive tumor microenvironment
Ursula A. Matulonis
5 shared publications
- Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer
- Final results of BrUOG 354: A randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas.
- Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha–expressing recurrent ovarian cancer: An integrated safety summary
- BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and fulvestrant (FUL) in HR+/HER2− breast cancer (BC).
- Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer
David M. O’Malley
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
5 shared publications
- Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha–expressing recurrent ovarian cancer: An integrated safety summary
- 18/#499 Mirvetuximab soravtansine and carboplatin for treatment of patients with recurrent folate receptor alpha-positive platinum-sensitive ovarian cancer: a final analysis
- Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer
- 605P Population pharmacokinetic (PK) analysis of mirvetuximab soravtansine (MIRV) in patients with folate receptor α (FRα)-positive cancer
- Treatment monitoring utilizing ctDNA-based molecular residual disease detection in early-stage endometrial cancer
Heather A. Lankes
Chesapeake Research Consortium (US)
4 shared publications
- Fear of recurrence, emotional well-being and quality of life among long-term advanced ovarian cancer survivors
- Sex Hormones, Insulin, and Insulin-like Growth Factors in Recurrence of High-Stage Endometrial Cancer
- Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival
- Abstract A044: Application of HRDefine: a biomarker for identifying root causes of homologous recombination deficiency to a phase 3, randomized, placebo-controlled trial of veliparib in front-line treatment of advanced ovarian cancer (VELIA/GOG-3005)
Carly Bess Scalise
Natera (United States) (US)
4 shared publications
- Understanding the effect of mechanical forces on ovarian cancer progression
- Utilization of a 3-D tissue engineered model to investigate the effects of perfusion on gynecologic cancer biology
- A spatial proteomic study of platinum refractory HGSOC implicates dual AKT and WNT activity linked to an immunosuppressive tumor microenvironment
- A spatial proteomic study of platinum-refractory, high-grade serous ovarian cancer implicates dual AKT and WNT activity linked to an immunosuppressive tumor microenvironment
Michael Method
ImmunoGen (United States) (US)
4 shared publications
- Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha–expressing recurrent ovarian cancer: An integrated safety summary
- 18/#499 Mirvetuximab soravtansine and carboplatin for treatment of patients with recurrent folate receptor alpha-positive platinum-sensitive ovarian cancer: a final analysis
- Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer
- 605P Population pharmacokinetic (PK) analysis of mirvetuximab soravtansine (MIRV) in patients with folate receptor α (FRα)-positive cancer
Kathleen N. Moore
Oklahoma State University Oklahoma City (US)
4 shared publications
- BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and fulvestrant (FUL) in HR+/HER2− breast cancer (BC).
- 18/#499 Mirvetuximab soravtansine and carboplatin for treatment of patients with recurrent folate receptor alpha-positive platinum-sensitive ovarian cancer: a final analysis
- Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer
- Abstract A044: Application of HRDefine: a biomarker for identifying root causes of homologous recombination deficiency to a phase 3, randomized, placebo-controlled trial of veliparib in front-line treatment of advanced ovarian cancer (VELIA/GOG-3005)
Samuel C. Mok
The University of Texas MD Anderson Cancer Center (US)
3 shared publications
- SIO: A Spatioimageomics Pipeline to Identify Prognostic Biomarkers Associated with the Ovarian Tumor Microenvironment
- Fear of recurrence, emotional well-being and quality of life among long-term advanced ovarian cancer survivors
- Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival
Austin Miller
Roswell Park Comprehensive Cancer Center (US)
3 shared publications
- Fear of recurrence, emotional well-being and quality of life among long-term advanced ovarian cancer survivors
- Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival
- LBA34 Association of homologous recombination deficiency (HRD) with clinical outcomes in a phase III study of olaparib or cediranib and olaparib compared to platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer (PSOC): Biomarker analyses from NRG-GY004
Sara R. Savage
Baylor College of Medicine (US)
3 shared publications
- A highly annotated database of genes associated with platinum resistance in cancer
- Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer
- Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer
Anna Calinawan
Icahn School of Medicine at Mount Sinai (US)
3 shared publications
- A highly annotated database of genes associated with platinum resistance in cancer
- Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer
- Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer
Chenwei Lin
Fred Hutch Cancer Center (US)
3 shared publications
- A highly annotated database of genes associated with platinum resistance in cancer
- Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer
- Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer
Shrabanti Chowdhury
Icahn School of Medicine at Mount Sinai (US)
3 shared publications
- Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer
- Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer
- DAGBagM: learning directed acyclic graphs of mixed variables with an application to identify protein biomarkers for treatment response in ovarian cancer
Ana Oaknin
Vall d'Hebron Institute of Oncology
3 shared publications
- Final survival analysis of topotecan and paclitaxel for first-line treatment of advanced cervical cancer: An NRG oncology randomized study
- Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha–expressing recurrent ovarian cancer: An integrated safety summary
- 605P Population pharmacokinetic (PK) analysis of mirvetuximab soravtansine (MIRV) in patients with folate receptor α (FRα)-positive cancer
Robert L. Coleman
3 shared publications
- Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha–expressing recurrent ovarian cancer: An integrated safety summary
- 605P Population pharmacokinetic (PK) analysis of mirvetuximab soravtansine (MIRV) in patients with folate receptor α (FRα)-positive cancer
- Abstract A044: Application of HRDefine: a biomarker for identifying root causes of homologous recombination deficiency to a phase 3, randomized, placebo-controlled trial of veliparib in front-line treatment of advanced ovarian cancer (VELIA/GOG-3005)
Similar Researchers
Based on overlapping research topics
Eric D. Nelson
University of Arkansas at Little Rock
Disease Mechanisms Research
Genomics and Phylogenetic Studies
Cancer Cells and Metastasis
Michael Bauer
University of Arkansas for Medical Sciences
Disease Mechanisms Research
Genomics and Phylogenetic Studies
Cancer Cells and Metastasis
Mohammed S. Orloff
University of Arkansas for Medical Sciences
Cancer Genomics and Diagnostics
Disease Mechanisms Research
Genomics and Phylogenetic Studies
Christopher P. Wardell
University of Arkansas for Medical Sciences
Cancer Genomics and Diagnostics
Disease Mechanisms Research
Genomics and Phylogenetic Studies
James R. Lindsay
University of Arkansas at Fayetteville
Cancer Genomics and Diagnostics
Genomics and Phylogenetic Studies
Bioinformatics and Genomic Networks
Benjamin J. Swanson
University of Arkansas at Fayetteville
Disease Mechanisms Research
Genomics and Phylogenetic Studies
Cancer Cells and Metastasis